Evidence map›Paper›PMID 38349008›Full record

ArticlemAbs

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.

Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R Piccotti and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Recent advances in the regulation of CD47 by non-coding RNAs and its therapeutic potential in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Dan ZhuDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Haralambos HadjivassiliouDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Catherine JenningsDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
David MikolonDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Massimo AmmiranteOncogenesis Thematic Research Center, Bristol Myers Squibb, San Diego, CA, USA.
Sharmistha AcharyaDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Jon LloydDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Mahan AbbasianDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Rama Krishna NarlaOncogenesis Thematic Research Center, Bristol Myers Squibb, San Diego, CA, USA.
Joseph R PiccottiDepartment of Nonclinical Development, Bristol Myers Squibb, San Diego, CA, USA.
Katie StampDepartment of Nonclinical Development, Bristol Myers Squibb, San Diego, CA, USA.
Ho ChoDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Kandasamy HariharanDepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USA.
Bristol-Myers Squibb (Germany) · DEBristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cluster of differentiation 47 (CD47) is a transmembrane protein highly expressed in tumor cells that interacts with signal regulatory protein alpha (SIRPα) and triggers a "don't eat me" signal to the macrophage, inhibiting phagocytosis and enabling tumor escape from immunosurveillance. The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. To overcome those challenges a bispecific approach was taken. CC-96673, a humanized IgG1 bispecific antibody co-targeting CD47 and CD20, is designed to bind CD20 with high affinity and CD47 with optimally lowered affinity. As a result of the detuned CD47 affinity, CC-96673 selectively binds to CD20-expressing cells, blocking the interaction of CD47 with SIRPα. This increased selectivity of CC-96673 over monospecific anti-CD47 approaches allows for the use of wild-type IgG1 Fc, which engages activating crystallizable fragment gamma receptors (FcγRs) to fully potentiate macrophages to engulf and destroy CD20

Indexed as

Antibodies, BispecificLymphoma, Non-HodgkinNeoplasmsAnimalsCD47 AntigenImmunoglobulin GImmunotherapyPhagocytosisAntibodies, BispecificCD47 AntigenImmunoglobulin GCD20CD47detunenon-Hodgkin’s lymphomaphagocytosis

Identifiers

PMID38349008
PMCPMC10865928
OpenAlexW4391786534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.